Meg McCarrick
Plex Pharmaceuticals (United States)(US)IMGENEX India (India)(IN)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Peptidase Inhibition and Analysis, Blood Coagulation and Thrombosis Mechanisms, Quinazolinone synthesis and applications, Chromatin Remodeling and Cancer
Most-Cited Works
- → Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor(2011)114 cited
- → Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001(2021)37 cited
- → Design, Synthesis, and Activity of a Novel Series of Factor Xa Inhibitors: Optimization of Arylamidine Groups(2002)20 cited
- → Solid-phase synthesis of naphthylamidines as factor VIIa/tissue factor inhibitors(2005)14 cited
- → Abstract A026: Discovery of potent and selective CDK2 molecule glue degraders for the treatment of HR+/HER2- breast cancer, and CCNE1 amplified tumors(2025)1 cited
- → Abstract 6375: Discovery and characterization of novel, potent and selective CDK2 molecular glue degrader against CCNE1-amplified tumors(2025)1 cited
- → PPARδ AGONIST REN001 IMPROVES MITOCHONDRIAL FUNCTION IN SKELETAL MUSCLE: A POTENTIAL TREATMENT FOR PRIMARY MITOCHONDRIAL MYOPATHIES(2023)
- → Abstract 1653: Preclinical characterization of PLX-61639, a potent and orally bioavailable SMARCA2-selective monovalent direct degrader(2025)
- → Structure-based optimization of aminothiadiazole inhibitors of AKT(2023)
- → Crystal Structure of JNK3 complexed with CC-930, an orally active anti-fibrotic JNK inhibitor(2011)